Shuman, Glenn & Stecker Investigates Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Granted U.S. Patent Titled 'Treatment of circadian rhythm disorders'
Vanda Pharmaceuticals Up Over 21%, on Track for Highest Close Since April 2019 -- Data Talk
Why ESSA Pharma, AnaptysBio And More Are Moving Today
12 Health Care Stocks Moving In Thursday's Intraday Session
Vanda Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.
Recap: Vanda Pharmaceuticals Q4 Earnings
BRIEF-Vanda Pharmaceuticals Reports Fourth Quarter And Full Year 2020 Financial Results
Vanda Pharmaceuticals Sees FY21 Sales Guidance Of $270M-$300M Vs $279.4M Estimates
Vanda Pharmaceuticals Q4 EPS $0.15 Beats $0.14 Estimate, Sales $67.70M Beat $64.00M Estimate